Article · 5 Oct 2026
Conference abstract
Whitepaper on biosimilars and innovator biologics
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
With Biopharma products going offpatent and guidelines for cost effective Biosimilars being defined globally, there is a strategy that major biopharma companies need to adopt to counter this prevailing inclination of towards Biosimilars. Biologics have been offering solutions where small molecule drugs have failed to reach. The Biopharma addressed areas like cancer, arthritis are the areas of concern whose treatment was long awaited. Following a period of decline in new chemical entities they provided a much needed injection of innovation to drug treatment. The Biologics market was valued to be 108 billion USD for the year 2011 and is expected to grow at CAGR of 8% to 160 billion USD for the year 2016. Growing with this market is another market which is not something that Innovator biologic producer wants but they have no other go on the account of the product hitting the patent expiry period. They should adopt strategies to either retain the exclusivity or join the stream of growing biosimilars. chand PDF HTML
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Chanderkanth Gautam”